MKI67 and breast cancer: The LUMINA study ‘A prospective cohort study evaluating risk of local recurrence following BCS and endocrine therapy in low risk luminal A breast cancer’ is also using IHC, including oestrogen receptor, progesterone receptor, HER2 and Ki67 status to determine luminal A subtype and direct treatment [39].